Pipeline

  • Home
  • Science & Pipeline
  • Pipeline
Pipeline

Pioneering RNA Therapeutics for Metabolic Disorders

Canary Cure is at the forefront of medical innovation, leveraging the power of RNA therapeutics to revolutionize the treatment landscape metabolic disorders. Our cutting-edge pipeline harnesses the potential of gene silencing technology to precisely target the underlying genetic causes of obesity, MASH as well as metabolic dysfunction that impact other diseases.
Unlike first generation therapies that primarily focusing on symptom management through appetite suppression which Canary is targeting energy expenditure through the reprogramming of our energy storing white fat into energy burning beige fat, prioritizing fat loss, preservation of lean body mass, body composition improvement and overall health.
Delivering Sustained Metabolic Transformation
At the forefront of our pipeline is the first-in-class siRNA therapeutic (CCT-217) engineered to induce sustained metabolic transformation delivering significant weight loss while preserving lean mass and improving liver health with twice-yearly subcutaneous self-dosing. This gene-silencing modifier transforms white fat into metabolically active beige fat, driving sustained weight and fat loss through enhanced energy expenditure.
Our Focus
  • Obesity: Our novel siRNA therapeutics target the endocannabinoid and energy expenditure systems, promoting the browning of white fat to increase metabolism and facilitate sustainable healthy weight loss. Unlike conventional approaches, our therapies prioritize fat loss, preservation of lean body mass and body composition improvement. With the convenience of less frequent dosing and better safety profile, this gene silencing therapy offers a promising solution for individuals battling obesity and its associated metabolic complications.
  • Metabolic dysfunction-associated steatohepatitis (MASH): formerly known as nonalcoholic steatohepatitis (NASH), a severe form of fatty liver disease characterized by inflammation and liver damage which there is an urgent need for effective therapies. Canary’s siRNA mechanism of action, which promotes beigeing of white fat to improves metabolic function, has shown promise in reducing liver fat accumulation and inflammation, suggesting its potential to address the underlying metabolic dysfunction associated with MASH.
  • Metabolic Dysfunction: Leveraging its ability to starve hypermetabolic cells, our primary drug candidate, CCT217, precisely targets key pathways to significantly amplify the activity of metabolically active beige fat cells - specialized cells that excel at consuming nutrients and expending energy. By influencing metabolic adaptability, this siRNA therapy re-establishes balanced resource distribution within environments susceptible to abnormal cell growth like cancer. This dual-action mechanism not only cuts off fuel supplies for hyperactive metabolic states but also strengthens overall metabolic health by improving how the body responds to insulin and manages lipids. This is a pioneering approach for conditions caused by rigid metabolism.
  • Pediatric Obesity: We are exploring the use of RNA therapy to target the underlying genetic and metabolic causes of severe pediatric obesity. By addressing the root cause of the disease focusing on leptin deficiency, resistance and sensitivity, we aim to develop long-lasting and effective treatments designed for children.
Developing World’s First Treatment for 4H Leukodystrophy
Primarily a pediatric disease, this rare genetic disorder affects the nervous system causing developmental delays, motor difficulties, endocrine issues and other abnormalities. Using mRNA encased in LNP that delivers functional gene directly to affected cells. The goals is to enable the production of healthy protein to halt the progression of the disease and potentially restore function.
Companion Diagnostics for Early Detection and Intervention
In conjunction with our therapeutic efforts, we are also developing novel companion diagnostics that leverage miRNA biomarkers sourced from partner human clinical trials. These diagnostics hold the potential to detect complex diseases and cancers at their earliest stages, enabling timely intervention and maximizing the efficacy of our therapeutic approaches.
Partnering for Progress
We are dedicated to fostering collaborative partnerships that accelerate the development of our transformative therapies. We regularly engage with key partners to share pipeline updates and explore new avenues for therapeutic advancement.
Our Vision: Preserving Human Life
At the heart of our endeavors lies an unwavering commitment to preserving human life. Our pipeline of vectorized gene therapies represents a beacon of hope for individuals facing CNS proteinopathies and rare neurological diseases. We are driven by the unwavering belief that these groundbreaking therapies have the potential to halt disease progression, restore function, and transform the lives of countless individuals.
Canary DigiGENE miRNA Diagnostic overview
Our point of care diagnostic platform uses Al to read miRNA expression patterns in complex diseases at the earliest stages.
Studies have shown a clear distinction in miRNA expression patterns between disease sample and normal healthy samples. This is a heat map of four breast cancer patients showing separation of miRNA expression profiles in tumors and normal tissues.
Obesity and Metabolic Diseases
We are leveraging the power of RNA therapeutics to address the root causes of obesity and metabolic disorders by:
Modulating the Endocannabinoid System

Modulating the Endocannabinoid System

Our therapies target specific components of this system to regulate appetite, metabolism, and fat storage.

Promoting Browning of White Fat

Promoting Browning of White Fat

We aim to convert energy-storing white fat into energy-burning beige fat, increasing metabolic rate and promoting weight loss.

By targeting these pathways, we strive to provide safe and effective treatment options for individuals struggling with obesity, metabolic disorders and the associated co-morbidities.
Developing World’s First Treatment for 4H Leukodystrophy
Primarily a pediatric disease, this rare genetic disorder affects the nervous system causing developmental delays, motor difficulties, endocrine issues and other abnormalities. Using mRNA encased in LNP that delivers functional gene directly to affected cells. The goals is to enable the production of healthy protein to halt the progression of the disease and potentially restore function.
Companion Diagnostics for Early Detection and Intervention
In conjunction with our therapeutic efforts, we are also developing novel companion diagnostics that leverage miRNA biomarkers sourced from partner human clinical trials. These diagnostics hold the potential to detect complex diseases and cancers at their earliest stages, enabling timely intervention and maximizing the efficacy of our therapeutic approaches.
Partnering for Progress
We are dedicated to fostering collaborative partnerships that accelerate the development of our transformative therapies. We regularly engage with key partners to share pipeline updates and explore new avenues for therapeutic advancement.
Our Vision: Preserving Human Life
At the heart of our endeavors lies an unwavering commitment to preserving human life. Our pipeline of vectorized gene therapies represents a beacon of hope for individuals facing CNS proteinopathies and rare neurological diseases. We are driven by the unwavering belief that these groundbreaking therapies have the potential to halt disease progression, restore function, and transform the lives of countless individuals.
Canary DigiGENE miRNA Diagnostic overview
Our point of care diagnostic platform uses Al to read miRNA expression patterns in complex diseases at the earliest stages.
Studies have shown a clear distinction in miRNA expression patterns between disease sample and normal healthy samples. This is a heat map of four breast cancer patients showing separation of miRNA expression profiles in tumors and normal tissues.
How it Works

“Lab-on-a-Chip” with Cloud-based Analytics

DigiGENE™ Molecular Point-of-Care Test Platform

One Step Nucleic Acid Amplification Test
Portable and Reusable HUB

Portable and Reusable HUB

Cloud Enabled Mobile App

Cloud Enabled Mobile App

Sample Holder

Sample Holder

Disposable Multi-Target Cartridge

Disposable Multi-Target Cartridge

Pioneering RNA Therapy

We are revolutionizing healthcare by harnessing the power of cutting-edge RNA therapies to develop and deliver innovative treatments that addresses the root causes of diseases. We are committed to fostering a culture of scientific excellence and collaboration to create life-changing treatments that are safe, effective, and accessible to all.

Disclaimer: Canary Cure Therapeutics Inc’s website includes future planned care offerings, that are currently in development and are subject to regulatory approval before they are able to be commercialized

Quick Links

Useful Links

Quick Contact

  • 5063 N Service Road, Suite 100, Burlington, ON, Canada
  • info@canarycure.com

Follow Us

Twitter
Copyright © 2023 Canary Global Inc. All rights reserved.